Brightsurf Science News & Current Events

January 01, 2019
Editorial: A proposal to correct minority underrepresentation in clinical trials
In an editorial in CNS Spectrums, a neurologists takes the research community to task for its lack of minority representation in Phase III clinical trials for drugs to treat Multiple Sclerosis (MS) and proposes changes to the system.

Role of PCSK9 inhibitors in high risk patients with dyslipidemia
The purpose of this review is to present available data on the efficacy and safety of the two available PCSK9 inhibitors in patients with FH, and importantly to discuss potential differences between the two drugs.A comprehensive literature search was performed to identify available data from clinical studies evaluating the impact of evolocumab or alirocumab on lipid and CV parameters in patients with FH.

The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease
Data indicates that high intrahepatic or circulating PCSK9 levels increase muscle and liver lipid storage, adipose energy storage and hepatic fatty acids, as well as triglycerides storage and secretion, thus contributing to the pathogenesis of NAFLD.

Is very low LDL-C harmful?
Low-density Lipoprotein Cholesterol (LDL-C) is a major Cardiovascular (CV) risk factor.

Exploration of umbelliferone based derivatives as potent MAO inhibitors
Monoamine oxidase inhibitors are potential drug candidates within therapeutics of different neuropsychological and neurodegenerative disorders including anxiety, depression and Parkinson's disease.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.